Nasdaq

EDAP TMS Says FDA Grants Breakthrough Designation To Focal One For Rectal Endometriosis

(RTTNews) - EDAP TMS SA (EDAP) announced Monday that its Focal One platform has been granted Breakthrough Device designation by the US Food and Drug Administration (FDA) for the treatment of deep ...
FOX 10 Phoenix

FDA approves new device for teens with severe depression

The FDA has approved Transcranial Magnetic Stimulation (TMS), a non-drug, magnetic pulse device, for use in teens as young as 15 to treat severe depression. TMS is now an option for adolescents who ...
Healio

FDA approves TMS device for adolescents with major depressive disorder

Please provide your email address to receive an email when new articles are posted on . The Apollo TMS device was previously FDA cleared for treating MDD in adults. TMS offers a non-pharmacologic ...
Nasdaq

Cortechs.ai and EDAP TMS SA Announce Successful First OnQ Prostate-Assisted Focal One® HIFU Procedure at UCSF Prostate Cancer Center

The first OnQ Prostate-assisted Focal One® Robotic HIFU procedure was successfully performed at UCSF, improving prostate cancer treatment precision. Cortechs.ai and EDAP TMS have announced the ...
Morningstar

Zeta Surgical® AI-powered TMS Navigation System Receives FDA 510(k) Clearance

BOSTON, Oct. 13, 2025 /PRNewswire/ -- Zeta Surgical today announced that its Zeta TMS Navigation System has received 510(k) clearance from the U.S. Food and Drug Administration (FDA). The device is ...
The Courier-Journal

Exploring How Well TMS Therapy Works: New Resource Released by Moment of Clarity

Moment of Clarity has released a new resource titled “Transcranial Magnetic Stimulation (TMS) Success Rate“, now available online. The article explores the effectiveness of TMS therapy in treating ...